Munich Cancer Registry



- Incidence and Mortality
- Selection Matrix
- Homepage
- Deutsch

ICD-10 D32: Meninges neoplasm



Survival

Munich Cancer Registry Cancer Registry Bavaria - Upper Bavaria Regional Center at Klinikum Grosshadern/IBE Marchioninistr. 15 Munich, 81377 Germany

https://www.tumorregister-muenchen.de/en

https://www.tumorregister-muenchen.de/en/facts/surv/sD32__E-ICD-10-D32-Meninges-neoplasm-survival.pdf

Index of figures and tables

Fig./Tbl		Page
1a	Relative survival by period of diagnosis (chart)	3
1b	Survival by period of diagnosis (table)	3
2a	Survival by sex (chart)	4
2b	Survival by sex (table)	4
3a	Relative survival by age category (chart)	5
3b	Survival by age category (table)	5




Figure 1a. Relative survival of patients with meninges neoplasm by period of diagnosis. Included in the evaluation are 3,042 cases diagnosed between 1988 and 2020.

The presented survival curves are derived from clinical records with valid follow-up informations, which means that death certificate cases (DCO) cases are omitted from the analysis. With this one restriction, the MCR has provided populationbased statistics since 1998, collecting data on all cancer cases in the region of southern Bavaria. Historical data of previous time periods can be heavily selected, therefore, univariate survival comparisons of the presented time periods must be carefully considered. Nonetheless, all calculable survival curves are depicted to facilitate the comparison of long time follow-up analyses of relative survival between particular cancers.

	Period of diagnosis						
		1988-1997		1998-2006		2007+	
		n=132		n=1,003		n=1,	907
	Years	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %
	0	100.0	100.0	100.0	100.0	100.0	100.0
	1	100.0	100.7	96.4	97.6	96.1	97.4
	2	100.0	101.4	95.5	97.9	94.7	97.5
	3	100.0	102.1	94.1	97.7	92.8	97.0
	4	100.0	102.8	92.8	97.6	91.1	96.7
	5	98.5	102.6	91.3	97.4	89.2	96.2
	6	97.7	103.0	89.9	97.4	87.9	96.4
	7	96.9	103.2	88.8	97.6	85.6	95.5
	8	96.2	103.6	86.6	96.9	84.3	95.7
	9	95.4	103.9	84.7	96.3	82.5	95.5
	10	93.1	102.4	82.2	95.2	80.3	94.9
	Median	27.5					

Table 1b. Observed (obs.) and relative (rel.) survival of patients with meninges neoplasm by period of diagnosis for period 1988-2020 (N=3,042).




Figure 2a. Survival of patients with meninges neoplasm by sex. Included in the evaluation are 2,910 cases diagnosed between 1998 and 2020.

	Sex				
	Ma	ale	Ferr		
	n=7	757	n=2,153		
Years	obs. %	obs. % rel. %		rel. %	
0	100.0	100.0	100.0	100.0	
1	95.2	97.1	96.5	97.7	
2	93.6	97.1	95.4	97.8	
3	90.1	95.4	94.4	98.0	
4	88.1	95.0	93.0	97.8	
5	86.1	94.9	91.3	97.3	
6	84.8	95.3	89.9	97.2	
7	83.3	95.6	88.0	96.6	
8	80.0	93.9	86.9	96.9	
9	77.9	93.7	85.1	96.5	
10	75.6	92.9	82.9	95.6	
11	73.4	92.3	81.2	95.2	
12	70.7	91.1	79.2	94.5	
13	66.6	87.7	78.0	94.8	
14	64.5	87.0	76.5	94.9	
15	63.7	88.3	75.4	95.5	
Median					

Table 2b. Observed (obs.) and relative (rel.) survival of patients with meninges neoplasm by sex for period 1998-2020 (N=2,910).




Figure 3a. Relative survival of patients with meninges neoplasm by age category. Included in the evaluation are 2,910 cases diagnosed between 1998 and 2020.

		Age category							
		0-49	yrs	50-59 yrs		60-69 yrs		70+ yrs	
		n=6	689	n=7	n=700		733	n=788	
	Years	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %
	0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
	1	99.6	99.6	99.3	99.6	96.9	97.9	89.9	93.3
	2	99.4	99.6	98.2	99.1	96.5	98.4	86.9	93.6
	3	99.2	99.5	97.1	98.5	95.1	98.2	83.1	93.4
	4	98.9	99.4	96.5	98.3	93.6	98.0	79.4	93.3
	5	98.9	99.5	95.8	98.2	92.2	97.9	74.8	92.0
	6	98.4	99.3	95.5	98.4	91.7	98.7	71.1	91.8
	7	98.0	99.1	94.9	98.4	89.6	98.2	67.3	91.8
	8	97.8	99.1	93.3	97.6	88.3	98.5	63.9	92.3
	9	97.6	99.2	92.7	97.7	86.4	98.1	59.4	91.5
	10	96.8	98.7	91.5	97.5	84.9	98.6	53.6	88.5
	Median					22.0		11.3	

Table 3b. Observed (obs.) and relative (rel.) survival of patients with meninges neoplasm by age category for period 1998-2020 (N=2,910).

Shortcuts

MCR	Munich Cancer Registry, Germany					
NCI SEER UICC	National Cancer Institute, USA Surveillance, Epidemiology, and End Results, USA Union for International Cancer Control, Geneva					
DCO NA NOS	Death certificate only Not available Not otherwise specified	Death certificate provides the only notification to the registry.				
OS	Overall/Observed survival	Overall/Observed survival (Kaplan-Meier estimate) Date of entry: diagnosis Event: death from any cause				
RS	Relative survival	Survival compared to "general population", ratio of observed to expected survival (Ederer II method), reflecting cancer specific survival				
AS	Assembled survival	Assembled chart of observed, expected, relative survival				
CS	Conditional survival	Survival probability under the condition of surviving a given period of time				
TTP	Time to progression	Time to first progression / relapse Date of entry: diagnosis Event: (progression / relapse): first local-, lymph node recurrence, distant metastasis or unspecified progression				
	1-КМ	1 minus Kaplan-Meier estimator ("inverse" Kaplan-Meier estimator)				
	CI	Cumulative incidence Death as competing risk (according to Kalbfleisch und Prentice)				
PPS	Post-progression survival	Survival since first progression / relapse (Kaplan-Meier estimate) Date of entry (progression / relapse): first local-, lymph node recurrence, distant metastasis or unspecified progression Event: death from any cause				

Recommended Citation

Munich Cancer Registry. Survival ICD-10 D32: Meninges neoplasm [Internet]. 2022 [updated 2022 Apr 15; cited 2022 Jun 1]. Available from: https://www.tumorregister-muenchen.de/en/facts/surv/sD32_E-ICD-10-D32-Meninges-neoplasm-survival.pdf

Copyright

The content of the public web site provided by the Munich Cancer Registry is available worldwide and free of charge. All documents are free to download, utilize, copy, print-out and distribute, providing that the MCR is referenced.

Disclaimer

The Munich Cancer Registry reserves the right to not be responsible for the topicality, correctness, completeness or quality of the information provided. Liability claims regarding damage caused by the use of any information provided, including any kind of information which is incomplete or incorrect, will therefore be rejected.